Secondary efficacy end points based on prior treatment
| . | Prior IMiD . | Prior BTZ + IMiD . | ≥2 prior regimens including BTZ and an IMiD . | |||
|---|---|---|---|---|---|---|
| PAN-BTZ-Dex (n = 245) . | Pbo-BTZ-Dex (n = 240) . | PAN-BTZ-Dex (n = 94) . | Pbo-BTZ-Dex (n = 99) . | PAN-BTZ-Dex (n = 73) . | Pbo-BTZ-Dex (n = 74) . | |
| Time to response, median (95% CI), mo | 1.45 (1.31-1.64) | 2.20 (1.54-6.34) | 1.58 (1.41-2.33) | NE (1.54-NE) | 1.54 (1.41-2.56) | NE (2.10-NE) |
| Duration of response, median (95% CI), mo | 13.14 (11.56-15.47) | 10.41 (7.95-11.53) | 11.99 (9.69-13.90) | 8.31 (6.14-12.32) | 11.99 (9.69-13.37) | 6.97 (4.86-13.40) |
| Time to progression/relapse/death, median (95% CI), mo | 12.68 (10.94-14.16) | 7.62 (6.31-8.31) | 12.25 (8.08-14.03) | 6.05 (4.70-7.56) | 12.68 (8.34-14.19) | 4.99 (3.75-6.80) |
| . | Prior IMiD . | Prior BTZ + IMiD . | ≥2 prior regimens including BTZ and an IMiD . | |||
|---|---|---|---|---|---|---|
| PAN-BTZ-Dex (n = 245) . | Pbo-BTZ-Dex (n = 240) . | PAN-BTZ-Dex (n = 94) . | Pbo-BTZ-Dex (n = 99) . | PAN-BTZ-Dex (n = 73) . | Pbo-BTZ-Dex (n = 74) . | |
| Time to response, median (95% CI), mo | 1.45 (1.31-1.64) | 2.20 (1.54-6.34) | 1.58 (1.41-2.33) | NE (1.54-NE) | 1.54 (1.41-2.56) | NE (2.10-NE) |
| Duration of response, median (95% CI), mo | 13.14 (11.56-15.47) | 10.41 (7.95-11.53) | 11.99 (9.69-13.90) | 8.31 (6.14-12.32) | 11.99 (9.69-13.37) | 6.97 (4.86-13.40) |
| Time to progression/relapse/death, median (95% CI), mo | 12.68 (10.94-14.16) | 7.62 (6.31-8.31) | 12.25 (8.08-14.03) | 6.05 (4.70-7.56) | 12.68 (8.34-14.19) | 4.99 (3.75-6.80) |